These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33149103)

  • 1. Circulating angiogenic factors are associated with progression to preeclampsia and the occurrence of adverse outcomes in women with gestational hypertension.
    Nolasco-Leaños AG; Ramírez-Valenzuela KL; Carrillo-Juárez RI; Molina-Pérez CJ; Isordia-Salas I; Leaños-Miranda A
    J Hypertens; 2021 Mar; 39(3):573-580. PubMed ID: 33149103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenic markers and their longitudinal change for predicting adverse outcomes in pregnant women with chronic hypertension.
    Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
    Am J Obstet Gynecol; 2021 Sep; 225(3):305.e1-305.e14. PubMed ID: 33812812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential plasma angiogenic factors levels in women with suspected preeclampsia.
    Baltajian K; Bajracharya S; Salahuddin S; Berg AH; Geahchan C; Wenger JB; Thadhani R; Karumanchi SA; Rana S
    Am J Obstet Gynecol; 2016 Jul; 215(1):89.e1-89.e10. PubMed ID: 26827880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical usefulness of angiogenic factors in women with chronic kidney disease and suspected superimposed preeclampsia.
    Molina-Pérez CJ; Nolasco-Leaños AG; Carrillo-Juárez RI; Leaños-Miranda A
    J Nephrol; 2022 Jul; 35(6):1699-1708. PubMed ID: 35353367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes.
    Lai J; Syngelaki A; Nicolaides KH; von Dadelszen P; Magee LA
    Am J Obstet Gynecol; 2021 May; 224(5):518.e1-518.e11. PubMed ID: 33166504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating angiogenic factors are related to the severity of gestational hypertension and preeclampsia, and their adverse outcomes.
    Leaños-Miranda A; Méndez-Aguilar F; Ramírez-Valenzuela KL; Serrano-Rodríguez M; Berumen-Lechuga G; Molina-Pérez CJ; Isordia-Salas I; Campos-Galicia I
    Medicine (Baltimore); 2017 Jan; 96(4):e6005. PubMed ID: 28121958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia.
    Leaños-Miranda A; Campos-Galicia I; Ramírez-Valenzuela KL; Chinolla-Arellano ZL; Isordia-Salas I
    Hypertension; 2013 May; 61(5):1118-25. PubMed ID: 23460287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble Endoglin As a Marker for Preeclampsia, Its Severity, and the Occurrence of Adverse Outcomes.
    Leaños-Miranda A; Navarro-Romero CS; Sillas-Pardo LJ; Ramírez-Valenzuela KL; Isordia-Salas I; Jiménez-Trejo LM
    Hypertension; 2019 Oct; 74(4):991-997. PubMed ID: 31446801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The additive role of angiogenic markers for women with confirmed preeclampsia.
    Suresh S; Patel E; Mueller A; Morgan J; Lewandowski WL; Verlohren S; von Dadelszen P; Magee LA; Rana S
    Am J Obstet Gynecol; 2023 May; 228(5):573.e1-573.e11. PubMed ID: 36356699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analysis on the roles of angiogenesis-related factors including serum vitamin D, soluble endoglin (sEng), soluble fms-like tyrosine kinase 1 (sFlt1), and vascular endothelial growth factor (VEGF) in the diagnosis and severity of late-onset preeclampsia.
    Cim N; Kurdoglu M; Ege S; Yoruk I; Yaman G; Yildizhan R
    J Matern Fetal Neonatal Med; 2017 Jul; 30(13):1602-1607. PubMed ID: 27658884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.
    Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ
    Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble Endoglin and Uterine Artery Flow Doppler Ultrasonography as Markers of Progression to Preeclampsia in Women with Gestational Hypertension.
    Molina Pérez CJ; Nolasco Leaños AG; Carrillo Juárez RI; Berumen Lechuga MG; Isordia Salas I; Leaños Miranda A
    Gynecol Obstet Invest; 2021; 86(5):445-453. PubMed ID: 34662881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preeclampsia at term can be classified into 2 clusters with different clinical characteristics and outcomes based on angiogenic biomarkers in maternal blood.
    Chaiworapongsa T; Romero R; Gotsch F; Suksai M; Gallo DM; Jung E; Krieger A; Chaemsaithong P; Erez O; Tarca AL
    Am J Obstet Gynecol; 2023 May; 228(5):569.e1-569.e24. PubMed ID: 36336082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of the sFlt-1/PlGF (Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor) Ratio in Diagnosis or Misdiagnosis in Women With Clinical Diagnosis of Preeclampsia.
    Leaños-Miranda A; Graciela Nolasco-Leaños A; Ismael Carrillo-Juárez R; José Molina-Pérez C; Janet Sillas-Pardo L; Manuel Jiménez-Trejo L; Isordia-Salas I; Leticia Ramírez-Valenzuela K
    Hypertension; 2020 Sep; 76(3):892-900. PubMed ID: 32713272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First trimester serum angiogenic and anti-angiogenic factors in women with chronic hypertension for the prediction of preeclampsia.
    Nzelu D; Biris D; Karampitsakos T; Nicolaides KK; Kametas NA
    Am J Obstet Gynecol; 2020 Apr; 222(4):374.e1-374.e9. PubMed ID: 31705883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
    N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A longitudinal analysis of angiotensin II type 1 receptor antibody and angiogenic markers in pregnancy.
    Aggarwal S; Sunderland N; Thornton C; Xu B; Hennessy A; Makris A
    Am J Obstet Gynecol; 2017 Feb; 216(2):170.e1-170.e8. PubMed ID: 27793555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between Adverse Maternal Clinical Outcomes and Imbalance of Cytokines and Angiogenic Factors in Preterm Preeclampsia.
    Nunes PR; Romao-Veiga M; Borges VTM; Matias ML; Ribeiro VR; Costa RAA; Peracoli MTS; Peracoli JC
    Rev Bras Ginecol Obstet; 2021 Sep; 43(9):669-675. PubMed ID: 34670301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preeclampsia at term: evidence of disease heterogeneity based on the profile of circulating cytokines and angiogenic factors.
    Chaiworapongsa T; Romero R; Gomez-Lopez N; Suksai M; Gallo DM; Jung E; Berry SM; Awonuga A; Tarca AL; Bryant DR
    Am J Obstet Gynecol; 2024 Apr; 230(4):450.e1-450.e18. PubMed ID: 37806612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gestational angiogenic biomarker patterns in high risk preeclampsia groups.
    Maynard SE; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Moore Simas TA
    Am J Obstet Gynecol; 2013 Jul; 209(1):53.e1-9. PubMed ID: 23517919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.